RxDoctor Payments DataLook up a doctor →

Mary Hughes, MD

Neurology · Greenville, SCNPI 1275643561

Payments from drug & device makers

$6,307,972in general payments, 2019–2025

Across 1,509 payments — averaging $4180.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.7M
  • Sanofi$1.2M
  • Genentech, Inc.$948K
  • TG Therapeutics, Inc.$286K
  • EMD Serono, Inc.$238K
  • Adamas Pharmaceuticals, Inc.$177K
  • plus $773K from 54 others
$16,969in research payments, 2019–2025

Across 22 payments — averaging $771.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$12K
  • Pfizer$3K
  • Sanofi US Services Inc.$2K
  • Novartis Pharma AG$77

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis105$2,721,646
Sanofi147$1,164,315
Genentech, Inc.118$948,006
TG Therapeutics, Inc.47$285,941
EMD Serono, Inc.260$238,297
Adamas Pharmaceuticals, Inc.51$176,920
Eli Lilly13$145,953
AbbVie(2 entities)59$130,071
Biogen51$117,957
Roche Products Limited130$82,070
Amgen(2 entities)59$64,419
Lilly USA, LLC48$32,538
F. Hoffmann-la Roche AG7$31,000
Teva Pharmaceuticals USA, Inc.177$28,620
Biohaven Pharmaceutical Holding Company Ltd.13$23,420
Genentech USA, Inc.34$20,331
Jazz Pharmaceuticals Inc.4$19,319
Pfizer19$19,017
Alkermes, Inc.14$15,399
Biohaven Pharmaceuticals, Inc.13$14,685
E.r. Squibb & Sons, L.L.C.9$9,674
Merck Kgaa2$5,939
Greenwich Biosciences, Inc.1$5,525
Bristol Myers Squibb30$2,526
Onmark, Inc.1$1,400
Mckesson Specialty Care Distribution, LLC1$525
Supernus Pharmaceuticals, Inc.15$231
Octapharma USA, Inc.2$207
Acadia Pharmaceuticals Inc8$206
AstraZeneca9$203
Argenx US, Inc.4$137
Eisai Inc.5$133
Takeda Pharmaceuticals U.S.A., Inc.5$125
Hyperfine Operations, Inc.1$117
Johnson & Johnson2$108
Banner Life Sciences, LLC3$84
Vanda Pharmaceuticals Inc.3$74
Tonix Medicines, Inc.2$66
Intrafusion GP, LLC3$64
Cycle Pharmaceuticals Inc2$50
Neurocrine Biosciences, Inc.2$47
Otsuka America Pharmaceutical, Inc.2$45
Medtronic(2 entities)2$42
Axsome Therapeutics, Inc.2$42
UCB, Inc.1$41
Acorda Therapeutics, Inc2$39
Bausch Health US, LLC3$39
ANI Pharmaceuticals, Inc.1$35
MDD US Operations, LLC2$32
Merz Pharmaceuticals, LLC1$31
Mylan Specialty L.p.1$31
Amneal Pharmaceuticals LLC1$29
Hospira, Inc.1$27
Impel Pharmaceuticals LLC1$24
Abbott1$24
Grifols USA, LLC1$24
Arbor Pharmaceuticals, Inc.2$24
Avanir Pharmaceuticals, Inc.2$23
Harmony Biosciences LLC1$19
Upsher-smith Laboratories LLC1$13

How this compares

$6,307,972 in reported general payments places this provider in the 95th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina →

Medicare billing

Part B allowed, 2024
$1,041,246
Medicare patients
260
Services billed
26,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Greenville

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →